Myelodysplastic syndromes

Published on 04/03/2015 by admin

Filed under Hematology, Oncology and Palliative Medicine

Last modified 04/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1257 times

18 Myelodysplastic syndromes

Myelodysplastic syndromes (MDSs) are acquired clonal hematological disorders characterized by normocellular/hypercellular marrow, ineffective hematopoiesis that leads to progressive cytopenia, and dysplasia in peripheral blood, reflecting maturation defects in erythrocytes, leukocytes, and/or platelets.

MDSs are heterogeneous and have a multitude of expressions; however, two morphologic findings are common to all types of MDS: the presence of progressive cytopenias in spite of a cellular bone marrow and dyspoiesis in one or more cell lines. Subtypes of the 2008 World Health Organization classification of MDSs are listed in Box 18-1.

Dyserythropoiesis

Evidence of dyserythropoiesis (Figure 18-1, A-I) may include any or all of the following: oval macrocytes, hypochromic microcytes, dimorphic erythrocyte population, erythrocyte precursors with more than one nucleus, abnormal nuclear shapes, nuclear bridging, uneven cytoplasmic staining, and/or ringed sideroblasts.